

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Atlas Venture Fund IX, L.P.</u>  (Last) (First) (Middle) 56 WAREHAM STREET, FLOOR 3  (Street) BOSTON MA 02118  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Surface Oncology, Inc. [ SURF ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 12/17/2020	
4. If Amendment, Date of Original Filed (Month/Day/Year) 12/21/2020		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/17/2020		S		1,700,000 <sup>(1)</sup>	D	\$8.1 <sup>(2)(4)</sup>	2,945,453	D <sup>(3)</sup>	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)					

1. Name and Address of Reporting Person\*  
Atlas Venture Fund IX, L.P.  
 (Last) (First) (Middle)  
 56 WAREHAM STREET, FLOOR 3  
 (Street)  
 BOSTON MA 02118  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Atlas Venture Associates IX, L.P.  
 (Last) (First) (Middle)  
 56 WAREHAM STREET, FLOOR 3  
 (Street)  
 BOSTON MA 02118  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Atlas Venture Associates IX, LLC  
 (Last) (First) (Middle)  
 56 WAREHAM STREET, FLOOR 3  
 (Street)  
 BOSTON MA 02118  
 (City) (State) (Zip)

(City)

(State)

(Zip)

**Explanation of Responses:**

1. Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP") is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of Atlas IX, AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed to an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
2. The high, low and average for the shares sold were all \$8.10. Each of the Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4.
3. Represents shares held directly by Atlas IX. The general partner of the Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaims Section 16 beneficial ownership of the securities held by the Atlas IX except to the extent of its pecuniary interest therein, if any.
4. This Amendment to the Form 4 originally filed by the Reporting Persons on December 21, 2020 is filed to amend the share price in Table I from \$18.10 to \$8.10.

Atlas Venture Associates IX,  
L.P., By: Atlas Venture  
Associates IX, LLC, its 12/21/2020  
general partner, By: /s/ Frank  
Castellucci, General Counsel

Atlas Venture Associates IX,  
LLC, By: /s/ Frank 12/21/2020  
Castellucci, General Counsel

Atlas Venture Fund IX, L.P.  
By: Atlas Venture Associates  
IX, L.P, its general partner, 12/21/2020  
By: Atlas Venture Associates  
IX, LLC, its general partner  
By: /s/ Frank Castellucci,  
General Counsel

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**